Skip to main content

Improving the Quality of Cancer Clinical Trials Workshop Summary (2008) / Chapter Skim
Currently Skimming:

References
Pages 102-106

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 102...
... • Develop a new funding mechanism to support the management of existing tissue repositories, and to support rational access to these valuable resources for testing biomarkers. Addressing some issues will require a great deal of work and research, Dr.
Read the entire page →
From page 103...
... with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 25(18S)
Read the entire page →
From page 104...
... 2003. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies.
Read the entire page →
From page 105...
... , a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
Read the entire page →
From page 106...
... 2007. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
Read the entire page →

Key Terms

  • clin oncol
  • cancer clinical
  • breast cancer
  • asco annual
  • meeting proceedings

  • lung cancer
  • factor receptor
  • cell carcinoma
  • tumor hypoxia
  • cancer cell

  • colorectal cancer
  • cytarabine versus
  • resonance imaging
  • positron emission
  • nucl med

  • support rational
  • adverse karyotype
  • drug discovery
  • receptor tyrosine
  • cancer randomly

  • clinical outcome
  • prognostic factor
  • randomized study
  • effective cancer
  • metastatic colorectal

  • gene mutations
  • adaptive randomized
  • iii study
  • bayesian clinical
  • assessment classification


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.